ECI Therapeutics
Private Company
Funding information not available
Overview
ECI Therapeutics is a private, preclinical-stage biotech leveraging a unique platform that fuses human platelet-rich plasma-derived growth factors with proprietary biomaterials (hyaluronic acid/chitosan) to create sustained-release therapeutics for tissue repair. Its initial focus is on significant ophthalmic markets, targeting neurotrophic keratitis (a rare disease) and the large, underserved dry eye disease population, with a broader pipeline extending into wound and burn care. Founded in 2018 and based in Cambridge, MA, the company is positioned to address conditions with high unmet need through a potentially safer, more efficacious, and patient-friendly biologic approach.
Technology Platform
Platform combining growth factors derived from human platelet-rich plasma (PRP) with proprietary excipients (hyaluronic acid or chitosan) for sustained-release topical formulations.
Opportunities
Risk Factors
Competitive Landscape
In dry eye disease, ECI would compete against established anti-inflammatories (Restasis, Xiidra, Cequa) and newer entrants. In neurotrophic keratitis, the direct competitor is Oxervate (cenegermin). In wound care, it would face other advanced biologics and cellular therapies. ECI's differentiation lies in its combination of multiple natural growth factors with a sustained-release biomaterial matrix.